Choosing a CAR for Relapsed/Refractory Large B-cell Lymphoma

被引：1
|
作者：
Abramson, Jeremy S. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
来源：
TRANSPLANTATION AND CELLULAR THERAPY | 2022年 / 28卷 / 10期
关键词：
AXICABTAGENE CILOLEUCEL; TISAGENLECLEUCEL; OUTCOMES; MULTICENTER;
D O I：
10.1016/j.jtct.2022.09.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：621 / 622
页数：2
相关论文
共 50 条
  • [1] CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma
    Gideon, Jacklyn
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (06) : 597 - 601
  • [2] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
  • [3] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [4] NEW TREATMENT FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2021, 121 (06) : 21 - 22
  • [5] Tisagenlecleucel Approved in Relapsed/Refractory Large B-Cell Lymphoma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (06) : 397 - 397
  • [6] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [7] Clinical phenotypes of CAR-T-cell related hematotoxicity in relapsed/refractory large B-cell lymphoma
    Rejeski, K.
    Sesques, P.
    Berger, C.
    Jentzsch, L.
    Mougiakakos, D.
    Froelich, L.
    Bucklein, V
    Blumenberg, V
    Schmidt, C.
    Jallades, L.
    Fehse, B.
    Faul, C.
    Weigert, O.
    Dreyling, M.
    von Bergwelt-Baildon, M.
    Mackensen, A.
    Bethge, W.
    Ayuk, F.
    Bachy, E.
    Salles, G.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 45 - 46
  • [8] Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy
    Perrone, Salvatore
    Lopedote, Paolo
    Levis, Mario
    Di Rocco, Alice
    Smith, Stephen Douglas
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 215 - 232
  • [9] Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All
    Zelenetz, Andrew D.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (12): : 1764 - 1766
  • [10] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
12345